The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Advances in mouse models for studying CLL and Richter’s transformation
Elisa Ten Hacken, PhD, Weill Cornell Medicine, New York City, NY, discusses the available mouse models for studying chronic lymphocytic leukemia (CLL) and Richter’s transformation, focusing on both genetically engineered and PDX mouse models. Her team has made advances using CRISPR-Cas9 to introduce complex genetic alterations reflective of human disease, allowing the testing of immunotherapies in these models. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
